Detection of glucose transporter 1 in living cells for assessment of tumor development and therapy using an electrochemical biosensor

The expression level of glucose transporter 1 (GLUT-1) is highly correlated with tumor malignancy, making it a promising therapeutic target for cancer treatment. The detection of GLUT-1 expression level is significant for cancer discovery and valuating the efficacy of drug treatments. However, current methods for GLUT-1 detection primarily rely on traditional techniques. Therefore, the development of anon-destructive in vivo monitoring system would be invaluable for assessing GLUT-1 expression and tumor responses to various drugs. In this study, an electrochemical platform for detection of GLUT-1 on living cells was established using reduced graphene oxide-multi-wall carbon nanotube composite (rGO-MWCNT) as a conductive coating and toluidine blue O (TBO)graphene-gold nanoparticle-GLUT-1 antibody as the electrochemical probe. The sensor demonstrated excellent performance in detecting GLUT-1 on cells with a linear range of 10 - 105 cells/mL, good stability and selectivity. The sensor successfully detected GLUT-1 expressions in multiple tumor cell types, including those treated with siRNA or drugs, and the results were consistent with those obtained from traditional methods such as flow cytometry, western blotting, and immunofluorescence. The sensor is promising in evaluating the malignant level of tumor cells, distinguishing glucose uptake pathways in tumor cells, reducing medical costs, and facilitating the translation of electrochemical sensing technology to the clinical settings.

Automated summary

In this study, an electrochemical platform for detecting GLUT-1 on living cells was developed using a composite of reduced graphene oxide-multi-wall carbon nanotube. The sensor demonstrated good performance in detecting GLUT-1 expression on cells and showed consistency with traditional detection methods. It has the potential to assess malignancy level and glucose uptake pathways in tumor cells while reducing medical costs.